Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Coyle

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Graduate Medical Education|January 10, 2014
Testing a site visit approach for the next accreditation systemJohn Coyle, Serge Martinez, William W Robertson, et al.
Investigational New Drugs|January 7, 2004
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectumMelanie E Royce, Eric K Rowinsky, Paulo M Hoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignanciesMitchell A Garrison, Lisa A Hammond, Charles E Geyer, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Graduate Medical Education|January 10, 2014
Testing a site visit approach for the next accreditation systemJohn Coyle, Serge Martinez, William W Robertson, et al.
Investigational New Drugs|January 7, 2004
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectumMelanie E Royce, Eric K Rowinsky, Paulo M Hoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignanciesMitchell A Garrison, Lisa A Hammond, Charles E Geyer, et al.
Pageof 1